Survival benefit of neoadjuvant chemotherapy in HR+/HER2- early breast cancer stratified by luminal B status and clinical risk: a real-world cohort study in a Chinese population.

Front Oncol · 2026 · PMC13112060 · PMID 42052472

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although some comparisons did not reach statistical significance, the overall direction consistently supported a potential benefit of NACT.

also in 111,027 other papers

an overall trendno p-value reported

In the prespecified high-risk Luminal B subgroup (characterized by Luminal B biology plus high T/N stage and Ki-67), the survival curves showed an overall trend of separation.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.